Abstract
The prolactin lowering activity of dihydroergokryptine was investigated both in rats and in humans. The drug was administered orally at the doses of 0.2, 1 and 5 mg/Kg to intact or reserpinized male rats. Nine male adult volunteers were given 300 mg cimetidine iv 90 min after receiving 2, 3 or 4.5 mg of dihydroergokryptine and 3, 4.5 and 6.75 mg of dihydroergocristine or placebo per os in a randomized, cross-over design. Eight young adult males were injected im with 10 mg sulpiride 120 min after randomly receiving dihydroergokryptine 2.5 and 5 mg or placebo in a cross-over manner. Finally, five healthy young women were given dihydroergokryptine 2.5 and 5 mg, bromocriptine 2.5 mg and placebo in a cross-over design. Dihydroergokryptine caused a strong, long-lasting, dose-dependent fall of plasma prolactin concentrations in both rats and humans. Moreover, it inhibited the reserpine-induced rise of plasma prolactin in rats, as well as the cimetidine-or sulpiride-induced hyperprolactinemia in humans. Dihydroergokryptine proved twice as potent as dihydroergocristine and about half as potent as bromocriptine. Effective doses of both dihydrogenated ergot alkaloids were much better tolerated than bromocriptine.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Williams L.T., Lefkowitz R.J. Alpha-adrenergic receptor identification by [3H] dihydroergokryptine binding. Science 192: 791, 1976.
Williams L.T., Mullikin D., Lefkowitz R.J. Identification of alpha-adrenergic receptors in uterine smooth muscle membranes by [3H] dihydroergokryptine binding. J. Biol. Chem. 251: 6915, 1976.
Goldstein M., Lew J.Y., Hata F., Lieberman A. Binding interactions of ergot alkaloids with monoaminergic receptors in the brain. Gerontology 24(Suppl. 1): 76, 1978.
Davis J.N., Strittmatter W.J., Hoyler E., Lefkowitz R.J. [3H] dihydroergokryptine binding in rat brain. Brain Res. 132: 327, 1977.
Caron M.G., Beaulieu M., Raymond V., Gagné B., Drouin J., Lefkowitz R.J., Labrie F. Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H] dihydroergokryptine binding with the dopaminergic control of prolactin release. J. Biol. Chem. 253: 2244, 1978.
Libertun C., Larrea G.A., Vacas M.I., Cardinali D.P. [3H] dihydroergokryptine binding in anterior pituitary and prolactin secretion: further evidence of brain regulation of adenohypophyseal receptors. Endocrinology 107: 1905, 1980.
Flückiger E., Del Pozo E. Ergot derivates and pituitary hormones. In: Müller E.E. (Ed.), Neuroactive drugs in endocrinology. Elsevier/North-Holland Biomedical Press, Amsterdam, 1980, p. 169.
Poli M., Caviezel F., Bosi E., Murari M., Bonetti M. Cimetidine and prolactin: a study with dihydroergocristine. Horm. Metab. Res. 14: 616, 1982.
Ferrari C., Romussi M., Benco R., Rampini P., Mailland F. Effect of dihydroergocristine administration on serum prolactin and growth hormone levels in normal, hyperprolactinemic, and acromegalic subjects: further evidence for pituitary dopamine deficiency in these conditions. Acta Endocrinol. (Kbh.) 103: 1, 1983.
D’Urso R., Falaschi P., Jellamo R., Rocco A., Ruggieri S., Agnoli A. Effect of dihydroergocristine on prolactin release from isolated and dispersed rat pituitary cells. Acta Ther. 8: 109, 1982.
Niswender G.D., Chen C.L., Midgley A.R. Jr., Meites J., Ellis S. Radioimmunoassay for rat prolactin. Proc. Soc. Exp. Biol. Med. 130: 793, 1969.
Sinha A.N., Selby F.W., Lewis U.J., Vanderlaan W.G. A homologous radioimmunoassay for human prolactin. J. Clin. Endocrinol. Metab. 36: 500, 1973.
Sibley D.R., Creese I. Interactions of ergot alkaloids with anterior pituitary D-2 dopamine receptors. Mol. Pharmacol. 23: 585, 1983.
Carlson H.E., Ippoliti A.F. Cimetidine, an H2 antihistamine, stimulates prolactin secretion in man. J. Clin. Endocrinol. Metab. 45: 367, 1977.
Gonzales-Villapando C., Szabo M., Frohman L.A. Central nervous system-mediated stimulation of prolactin secretion by cimetidine, a histamine H2-receptor antagonist: impaired responsiveness in patients with prolactin-secreting tumors and idiopathic hyperprolactinemia. J. Clin. Endocrinol. Metab. 51: 1417, 1980.
MacLeod R.M., Robyn C. Mechanism of increased prolactin secretion by sulpiride. J. Endocrinol. 72: 273, 1977.
Parlodel Physicians’ Desk Reference, 38th Edition, 1984, p. 1748.
Franks S., Horrocks P.M., Lynch S.S., Butt W.R., London D.R. Treatment of hyperprolactinemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment. Lancet 2: 659, 1981.
Liuzzi A., Chiodini P.G., Oppizzi G., Botalla L., Verde G., De Stefano L., Coluzzi G., Gräf K.J., Horowsky R. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans. J. Clin. Endocrinol. Metab. 46: 196, 1978.
Mannelli M., Delitala G., De Feo M.L., Maggi M., Cuomo S., Piazzini M., Guazzelli R., Serio M. Effect of different dopaminergic antagonists on bromocriptine-induced inhibition of norepinephrine release. J. Clin. Endocrinol. Metab. 59: 74, 1984.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Poli, M., Cocchi, D., Mailland, F. et al. Prolactin lowering effect of dihydroergokryptine in rat and in man. J Endocrinol Invest 9, 31–36 (1986). https://doi.org/10.1007/BF03348059
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03348059